Group 1: Nandu Power (南都电源) - Nandu Power focuses on the energy storage sector, providing lithium-ion and lead batteries, with a global presence in over 160 countries [1] - In the first half of 2025, the company expects revenue of approximately 3.923 billion yuan, a year-on-year decrease of 1.8 billion yuan, and a net profit of approximately -230 million yuan [1] - The company achieved a quarterly profit of approximately 34 million yuan in Q2, driven by high-margin orders in the global energy storage market and rapid growth in data center business [1] - Nandu Power has a current lithium battery cell capacity of 10 GWh and is expanding its new power storage integration capacity [1] - The company has secured multiple high-pressure lithium battery data center projects, with an order backlog of approximately 0.8 GWh [1] Group 2: Zhenhua Co., Ltd. (振华股份) - Zhenhua Co., Ltd. reported double-digit growth in export volumes, primarily driven by domestic demand [2] - The company maintains a cost-plus pricing strategy and has seen historical high gross margins in Q2, with limited expansion from competitors [2] - Cash flow has decreased due to accounts receivable and inventory, while the production of ultra-fine aluminum hydroxide has expanded [2] Group 3: Maide Medical (迈得医疗) - Maide Medical has a competitive advantage in the domestic contact lens market due to over 20 years of technical accumulation and short delivery times [3] - The company is in the expansion phase of its contact lens business, planning to commercialize through a CDMO and self-brand sales model [3] - The main business of the company is under pressure, but growth in blood purification equipment and drug-device combination products is expected to reverse the loss situation in 2024 [3] Group 4: Changcheng Fund (长城基金) - Changcheng Fund has an asset management scale of 349.902 billion yuan, ranking 29th among 210 funds [4] - The fund has 242 public funds under management, ranking 27th among 210 [4] - The best-performing public fund in the past year is Changcheng Health Mixed A, with a net value increase of 106.13% [4]

Core Viewpoint - The company is making progress in its contact lens business and aims to achieve commercialization within the year [1][4]. Group 1: Company Overview - As of August 15, 2025, the company's stock price closed at 18.33 yuan, up 4.09% from the previous week [1]. - The company has a total market capitalization of 3.047 billion yuan, ranking 69th out of 78 in the automation equipment sector and 4456th out of 5152 in the A-share market [1]. Group 2: Contact Lens Business Development - The domestic contact lens market is dominated by four major international players: Johnson & Johnson, CooperVision, Alcon, and Bausch & Lomb, with the industry still in its early stages in mainland China [1]. - The company is currently in the customer engagement and business development phase for its contact lens business, with online platforms being established to achieve commercialization this year [2]. - The company plans to integrate CDMO (Contract Development and Manufacturing Organization) with its own brand sales, starting with hydrogel products and later expanding to silicone hydrogel and functional soft lenses [2]. Group 3: Production Capacity and Quality - The company is applying for registration certificates for daily disposable soft contact lenses and currently operates four production lines, each with an annual capacity of 18 million pieces [2][4]. - The production yield of the contact lens lines is currently fluctuating as the company focuses on sample production and diversifying its product range [2]. Group 4: Future Plans and Financial Performance - The company will continue to focus on material research, product certification, brand launch, new product development, and cost optimization in its contact lens business [3]. - The company’s main business is under pressure due to reduced investment willingness from downstream clients and increased domestic competition, but blood purification equipment continues to grow due to domestic substitution [3]. - As of the end of 2024, the company has 21 orders for its drug-device combination products, which are expected to be a new growth point for 2025 [3][4]. - The company's contract liabilities reached 157.8464 million yuan, a 59.70% increase from the previous year, marking a three-year high, primarily driven by orders for drug-device combination and blood purification equipment [3][4].